Gemtuzumab ozogamicin: A review of its use in acute myeloid leukaemia

Drugs

Volumn 65, Issue 16, 2005, Pages 2405-2427

  Fenton, Caroline ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Acute myeloid leukaemia; Gemtuzumab ozogamicin; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Tolerability

Indexed keywords

AMIFOSTINE; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MITOXANTRONE; OBLIMERSEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANAPHYLAXIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRADYCARDIA; BRAIN HEMORRHAGE; CANCER SURVIVAL; CARDIOTOXICITY; CHILL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EPISTAXIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IC 50; INFECTION; INTERNALIZATION; IRON DEFICIENCY ANEMIA; LEUKEMIA REMISSION; LEUKOPENIA; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LUNG TOXICITY; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; NAUSEA AND VOMITING; NEUTROPENIA; PATIENT SELECTION; PLEURA EFFUSION; PNEUMONIA; RESPIRATORY FAILURE; REVIEW; SEPSIS; STEADY STATE; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHILD; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED;

EID: 27644470779     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200565160-00014     Document Type: Review

References (72)

1. Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol 2004; 5 (7): 443-50
2. National Cancer Institute. SEER (Surveillance, Epidemiology, and End Results) Cancer Statistics Review 1975-2002 [online]. Available from URL: http://seer.cancer.gov [Accessed 2005 May 19]
3. Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 2002; 52 (6): 363-71
4. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103 (2): 479-85
5. Wedding U, Bokemeyer C, Meran JG. Elderly patients with acute myeloid leukaemia: characteristics in biology, patients and treatment. Onkologie 2004; 27 (1): 72-82
6. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001 Jun; 7 (6): 1490-6
7. Tallman MS, Gilliland DG, Rowe JM. Drug therapy of acute myeloid leukemia. Blood 2005 Aug 15; 106 (4): 1154-63
8. Ferrara F, Palmieri S, Mele G. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia. Haematologica 2004; 89 (8): 998-1008
9. Sekeres MA, Stone RM. The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol 2002; 14 (1): 24-30
10. Ferrara F, Morabito F, Latagliata R, et al. Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsing after first complete remission. Haematologica 2001; 86: 814-20
11. Jackson GH, Taylor PRA. Acute myeloid leukaemia: optimising treatment in elderly patients. Drugs Aging 2002; 19 (8): 571-81
12. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Eng J Med 1994; 331: 896-903
13. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999 Oct; 107 (1): 69-79
14. Appelbaum FR. New targets for therapy in acute myeloid leuke-mia. Leukemia 2003; 17 (3): 492-5
15. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 2005 Feb; 19 (2): 176-82
16. Baer MR, Stewart CC, Dodge RK, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001; 97: 3574-80
17. Medical Research Council Working Parties on Leukaemia in Adults and Children. Acute Myeloid Leukaemia Trial 15 [online]. Available from URL: http://www.aml15.bham.ac.uk [Accessed 2005 Aug 17]
18. McGavin JK, Spencer CM. Gemtuzumab ozogamicin. Drugs 2001; 61 (9): 1317-22; discussion 1323-4
19. Jedema I, Barge RMY, van der Velden VHJ, et al. Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 2004 Feb; 18 (2): 316-25
20. Linenberger ML, Hong T, Flowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001 Aug 15; 98: 988-94
21. Walter RB, Raden BW, Cronk MR, et al. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood 2004 Jun 1; 103 (11): 4276-84
22. Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chem 2002; 13: 47-58
23. Matsui H, Takeshita A, Naito K, et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia 2002 May; 16 (5): 813-9
24. Walter RB, Raden BW, Kamikura DM, et al. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 2005 Feb 1; 105 (3): 1295-302
25. Walter RB, Raden BW, Hong TC, et al. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003 Aug 15; 102 (4): 1466-73
26. Takeshita A, Shinjo K, Naito K, et al. Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia 2005; 19: 1306-11
27. Arceci RJ, Sande J, Lange B, et al. Safety and efficacy of gemtuzumab ozogamicin (Mylotarg®) in pediatric patients with advanced CD33-positive acute myeloid leukemia. Blood 2005 Aug 15; 106 (4): 1183-8
28. van der Velden VHJ, Boeckx N, Jedema I, et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients. Leukemia 2004 May; 18 (5): 983-8
29. Wyeth Laboratories. Mylotarg® (gemtuzumab ozogamicin for injection) [online]. Available from URL: http:// www.wyeth.com/ [Accessed 2005 May 2]
30. Dowell JA, Korth-Bradley J, Liu H, et al. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 2001 Nov; 41 (11): 1206-14
31. Lee MD, Dunne TS, Siegel MM, et al. Calichemicins, a novel family of antitumour antibiotics. 1. Chemistry and partial structure of calichemicin γ-1 I. J Am Chem Soc 1987; 109: 3464-6
32. Amico D, Barbui AM, Erba E, et al. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood 2003 Jun 1; 101: 4589-97
33. Buckwalter M, Dowell JA, Korth-Bradley J, et al. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacol 2004 Aug; 44 (8): 873-80
34. Korth-Bradley JM, Dowell JA, King SP, et al. Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin. Pharmacotherapy 2001 Oct; 21: 1175-80
35. Larson RA, Sievers EL, Stadtmauer E.A., et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005 Oct 1; 104 (7): 1442-52
36. Roboz GJ, Knovich MA, Bayer RL, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leuk Lymphoma 2002 Oct; 43: 1951-5
37. Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004 Oct 1; 104 (7): 1995-9
38. Amadori S, Suciu S, Stasi R, et al. Gemtuzumab ozogamicin (Mylotarg.) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase II study of the European Organi-sation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia 2005 Oct; 19 (10): 1768-73
39. Nabhan C, Rundhaugen LM, Riley MB, et al. Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leuk Res 2005 Jan; 29 (1): 53-7
40. Amadori S, Suciu S, Willemze R, et al. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 2004 Aug; 89 (8): 950-6
41. De Angelo DJ, Stone RM, Durrant S, et al. Gemtuzumab ozogamicin (Mylotarg.) in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: two age-specific phase 2 trials [abstract no. 341]. Blood 2003 Nov 16; 102 (11 Part 1): 100.
42. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003 Dec 15; 102 (13): 4277-83
43. Stone RM, Moser B, Schulman P, et al. A dose escalation and phase II study of gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) for patients (pts) with refractory or relapsed acute myeloid leukemia (AML): CALGB 19902 [abstract no. 873]. Blood 2004; 104 (11 Pt 1): 249.
44. Tsimberidou A, Estey E, Cortes J, et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 2003 Mar 15; 97: 1481-7
45. Tsimberidou A, Cortes J, Thomas D, et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 2003 Oct; 27 (10): 893-7
46. Moore JO, Seiter K, Kolitz JE, et al. Phase 2 study of oblimersen sodium (G3139; Bcl-2 antisense; Genasense.) plus gemtuzumab ozogamcin (Mylotarg.) in elderly patients with relapsed acute myeloid leukemia (AML) [abstract no. 865]. Blood 2004; 104 (11 Pt 1): 247.
47. Tsimberidou AM, Estey E, Cortes JE, et al. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 2003 Dec; 52 (6): 449-52
48. Alvarado Y, Tsimberidou A, Kantarjian H, et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 2003 Jan; 51: 87-90
49. Estey EH, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamycin ('mylotarg') and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002 Jun 1; 99: 4222-4
50. 2 combined with intermediate dose aracytin and mitoxantrone (MIDAM) in relapsed/refractory CD33+ acute myeloid leukemia: a single center phase II experience [abstract no. 1811]. Blood 2004; 104 (11): 501-2
51. Venugopal P, Gregory SA, Raza A, et al. Phase II study of gemtuzumab ozogamycin (Mylotarg) combined with intensive induction chemotherapy using high dose ara-C and mitoxantrone followed by amifostine in poor prognosis acute myeloid leukemia: preliminary results [abstract no. 1323]. Blood 2002; 100 (11 Pt 1): 341a
52. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001 Jul 1; 19 (13): 3244-54
53. Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002 Sep; 16: 1627-36
54. Zwaan CM, Reinhardt D, Corbacioglu S, et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood 2003 May 15; 101 (10): 3868-71
55. Reinhardt D, Diekamp S, Fleischhack G, et al. Gemtuzumab ozogamicin (Mylotarg®) in children with refractory or relapsed acute myeloid leukemia. Onkologie 2004 Jun; 27 (3): 269-72
56. HOVON Stichting Hemato-Oncologie voor Volwassenen Nederland (Dutch hemato-oncology association). HOVON 43 AML [online]. Available from URL: http://www.hovon.nl [Accessed 2005 Aug 18]
57. National Cancer Institute. Clinical trials [online]. Available from URL: http://www.cancer.gov/clinicaltrials [Accessed 2005 May 24]
58. Wyeth Laboratories. Gemtuzumab ozogamicin phase 2 trials HSCT patient survival data, 2005. (Data on file)
59. Sievers EL, Spielberger R, Brunvand MW, et al. Gemtuzumab ozogamicin (Mylotarg.) as a single agent to evaluate safety and determine maximum tolerated dose in post hemopoeitic stem cell transplant patients with relapsed, CD33+ acute myeloid leukemia (AML) [abstract no. 1304]. Blood 2002 Nov 16; 100 (11 Pt 1): 336.
60. Sievers EL, Linenberger M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol 2001 Nov; 13 (6): 522-7
61. Larson RA. Current use and future development of gemtuzumab ozogamicin. Semin Hematol 2001 Jul; 38 (3 Suppl. 6): 24-31
62. Erba HP, Stadtmauer EA, Larson RA, et al. Risk assessment for hepatic veno-occlusive disease in patients treated with gemtuzumab ozogamicin (Mylotarg®) with or without hematopoietic stem cell transplantation [abstract no. 3241]. Blood 2003; 102: 871a
63. Erba HP, Stadtmauer EA, Larson RA, et al. Final results of a multivariate logistic regression analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin [abstract no. 1313]. Blood 2002; 100: 339a
64. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003 Sep 1; 102 (5): 1578-82
65. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology - Acute Myeloid Leukemia Version 2.2005 [online]. Available from URL: http://www.nccn.org/ professionals/physician_gls/pdf/aml.pdf [Accessed 2005 Mar 24]
66. European Society for Medical Oncology. ESMO minimum clinical recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients. Ann Oncol 2005; 16 Suppl. 1: i48-9
67. Ferrara F, Venditti A, Carellajr AM, et al. Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr. Eur J Haematol 2002; 69: 200-4
68. Kimby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in acute myeloid leukaemia: SBUgroup. Acta Oncol 2001; 40 (2/3): 231-52
69. Kern W, Aul C, Maschmeyer G, et al. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia 1998 Jul; 12 (7): 1049-55
70. Archimbaud E, Anglaret B, Thomas X, et al. Continuous-infusion daunorubicin and carboplatin for high-risk acute myeloid leukemia in the elderly. Leukemia 1992 Aug; 6 (8): 776-9
71. Rajvanshi P, Shulman HM, Sievers EL, et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002 Apr 1; 99: 2310-4
72. Kompetenznetz-leukäemien. Akute und chronisch leukämien [online]. Available from URL: http://www.kompetenznetz-leukaemie.de/kn_home_en/ [Accessed 2005 May 27]